| |
|
|
|
Oxford Global, Berlin, Germany
13-14 June 2016
Our Summit will consist of 7 interactive streams covering: - Target Based Discovery
- Screening and Assays: Enabling Technologies
- Novel Therapeutic Modalities and New Target Classes
- Supporting Innovation: Data and Information Management
- Discovery Chemistry: Latest Case Studies
- Drug Design: Novel Approaches
- Large Molecule Discovery Approaches
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
|
Invited Speakers:
|
|
- Tove Tuntland, Director Of Metabolism And Pharmacokinetics (MAP), Genomics Institute Of Novartis Research Foundation (GNF)
- Peter Dandliker, Director, ALIS Affinity Screening, Merck
- Thomas Steger-Hartmann, Head of Investigational Toxicology, Vice President, Bayer HealthCare
- Anil Nair, Head Of In Silico Drug Discovery, Sanofi-Aventis
- Ulrich Betz, Senior Director, Department Head Innovation & Entrepreneurship, Merck
- Guido Hanaeur, Scientific Director Translational Medicine, TAKEDA Pharmaceuticals
- Juergen Hammer, Roche Pharmaceutical Research and Early Development Center Head, Informatics/IT, Global Head, Data Science, Roche Innovation Center New York
- Harren Jhoti, President & CEO, Astex Pharmaceuticals
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
If you would like to receive any information regarding registrations, price and discounts, please contact g.alonso@oxfordglobal.co.uk
|
|
|
E-mail:
|
|
g.alonso@oxfordglobal.co.uk
|
|
|
|
|
|
|
|
|